Health/Medical Writers / Business Editors

BASKING RIDGE, N.J.--(BUSINESS WIRE)--MBTG--

Consortium Built to Educate and Introduce
New Treatments to Global Marketplace

Millennium Biotechnologies, Inc. (OTCBB: MBTG.OB), has partnered
with the Global Business Coalition on HIV/AIDS (GBC) to introduce
Millennium's products to the global business community. The GBC is an
alliance of over 170 international corporations leading the business
fight against the AIDS pandemic.
Millennium Biotechnologies is a pioneer in the research and
development of specialized nutritional products, namely Resurgex and
Resurgex-plus, which are patented, multi-action, multi-component
nutritional formulas designed to address the comprehensive needs of
individuals struggling with immuno-compromised conditions such as
HIV/AIDS as an adjunct to their medical care. In clinical trials both
products have been proven to have significant effect on the health and
well being of immuno-compromised patients.
"In partnering with the GBC's international alliance we are able
to educate people living and working with HIV/AIDS about the efficacy
of integrating medical nutrition therapy into their treatment regime
so they are able to maintain a healthy immune system as well as a
healthy lifestyle," said Jerry Swon, CEO, Millennium Biotechnologies.
"Our partnership with Millennium is a natural one, given that many
of our members have implemented comprehensive HIV/AIDS treatment
programs and are continually seeking to enhance these programs," said
Patricia Mugambi, director of corporate relations, GBC. "Nutrition is
an integral component of care and treatment regimens, and the GBC
remains committed to educating our global partners about the most
recent nutritional information and products available that can support
their ongoing efforts."
Millennium Biotechnologies joins the ranks of select national and
international companies dedicated to promoting the new and innovative
opportunities for the business sector to join the growing global
movement against this epidemic. For a complete list of GBC member
companies please visit www.businessfightsaids.org.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc., a wholly owned subsidiary of
Millennium Biotechnologies, Group Inc. is a pioneer in the research
and development and marketing of medical nutritional supplements.
Millennium owns the exclusive rights to RESURGEX(R) and RESURGEX
Plus(TM), multiple action nutritional formulas containing the
critically important, orally effective form of (SOD)/Gliadin
(Defenzyme(TM))) and several other essential nutritional components.
Millennium products are designed to assist in increasing energy,
maintaining lean muscle, reducing oxidative stress and supporting
immune function in patients with HIV/AIDS, Hepatitis C, cancer or
other immuno-compromised conditions as an adjunct to their medical
care. Additional information about Millennium Biotechnologies, Inc.,
is available at www.milbiotech.com.

About The Global Business Coalition on HIV/AIDS

The Global Business Coalition on HIV/AIDS (GBC) is the pre-eminent
organization leading the business fight against HIV/AIDS. With offices
in New York and Paris, the rapidly-expanding alliance of over 170
international companies is dedicated to combating the AIDS epidemic
through the business sector's unique skills and expertise. The mission
of the GBC is to harness the power of the global business community to
end the HIV/AIDS pandemic. For more information, please visit the GBC
website at www.businessfightsaids.org.

This news release contains forward-looking statements that are
based upon management's beliefs as well as on assumptions made by and
data currently available to management. This information which has
been, or in the future may be, included in reliance on the "safe
harbor" provisions on the Private Securities Litigation Reform Act of
1995, is subject to a number of risks and uncertainties, including but
not limited to uncertainty as to market acceptance of Resurgex and the
factors identified in the Company's 10-KSB and other documents filed
with the Securities and Exchange Commission. Actual results may differ
materially from those anticipated in such forward-looking statements
even if experience or future changes make it clear that any projected
results expressed or implied therein may not be realized. The Company
undertakes no obligation to update or revise any forward-looking
statements to reflect subsequent events or circumstances.

KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL MEDICAL MEDICAL SPORTS BIOTECHNOLOGY ALTERNATIVE MEDICINE MEDICAL
SOURCE: Millennium Biotechnologies, Inc.

CONTACT INFORMATION:
KCSA
Katie Bestenlehner / Anne Donohoe
212-896-1269 / 212-896-1261
kbest@kcsa.com / adonohoe@kcsa.com
or
Barbara Holmes
Director of Communications & Advocacy
The Global Business Coalition on HIV/AIDS
Tel: 212-846-5630
Fax: 212-846-1939
bholmes@businessfightsaids.org